ALPHARETTA, Ga., Sept. 9, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, senior vice president, chief financial officer, and chief transformation officer will participate in a fireside chat at CL King's virtual 22nd Annual Best Ideas Conference 2024 on Mon., Sept. 16 at approximately 9:30 a.m. Eastern Time.
A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site.
About Avanos Medical, Inc.
Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, we are committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. We develop, manufacture and market our recognized brands globally and hold leading market positions in multiple categories across our portfolio. For more information, visit Avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.
Last Trade: | US$18.68 |
Daily Change: | -0.47 -2.45 |
Daily Volume: | 170,487 |
Market Cap: | US$858.350M |
November 12, 2024 November 08, 2024 July 31, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB